Company / Cash & Equivalents
JRSIS HEALTH CARE Corp Cash & Equivalents History
FY2014-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$58.6K
FY2022
5-year range
$29.8K / $884.3K
FY2018-FY2022
Trend
+96.4%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2022 after 3 years of decline, reaching $58,616.
Based on SEC 10-K filings.
$58,616 in FY2022 with a 5-year CAGR of -41.9%.
Declined from $256,450 to $58,616 over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -41.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -41.9%, indicating a declining trend.
- In FY2022, cash & equivalents increased 96.4% year-over-year.
- Peak cash & equivalents was recorded in FY2014.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | - | - |
| FY2022 | $58.6K | +96.4% |
| FY2021 | $29.8K | -88.4% |
| FY2018 | $256.4K | -71.0% |
| FY2017 | $884.3K | -0.7% |
| FY2016 | $890.7K | +152.9% |
| FY2015 | $352.2K | -66.3% |
| FY2014 | $1.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026